Multiple Myeloma
Feature
Time to stop routine maintenance therapy in myeloma?
Research now suggests some multiple myeloma patients may not need indefinite, costly maintenance therapy after stem cell transplantation.
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
News
FDA panel voices concerns over 2 lymphoma accelerated approvals
FDA’s ODAC committee pressed for resolution on whether 2 lymphoma drugs, long on the U.S. market, actually deliver significant benefits to...
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Feature
Survival on the upswing in myeloma
Hematologists say that median lifespans are reaching 10 years or more after diagnosis.
Sponsored Supplement
Multiple Myeloma: A New Treatment Option for Newly Diagnosed, Transplant-Ineligible Patients
Conference Coverage
Debate: Should smoldering myeloma be treated?
After hearing two experts debate the evidence at the SOHO annual meeting, an audience seemed swayed to treat high-risk myeloma patients.
News
FDA approves motixafortide for stem cell mobilization in myeloma
Motixafortide has been approved by the FDA to help mobilize hematopoietic stem cells in autologous transplants for patients with multiple myeloma...
News from the FDA/CDC
FDA approves elranatamab for multiple myeloma
Elranatamab previously received Breakthrough Therapy Designation for relapsed or refractory multiple myeloma.
News
FDA OKs talquetamab, a first-in-class myeloma tx
Accelerated approval has been granted by the FDA to talquetamab-tgvs, a bispecific antibody, for patients with myeloma who have undergone at least...
From the Journals
Antibody shows promise in preventing GVHD
In translational research that shows potential for humans, an antibody blockade of the Notch signaling pathway prevents graft-versus-host-disease...
From the Journals
MM: Newest IKEMA results back isatuximab
Adding isatuximab to carfilzomib and dexamethasone creates ‘another effective triplet’ for relapsed/refractory multiple myeloma.